News Releases
BioCryst's Rapivab Receives FDA Approval for the Treatment of Acute Uncomplicated Influenza
BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved RAPIVAB (peramivir injection), an intravenous (i.v.) neuraminidase inhibitor for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days.
New Influenza Vaccine from Sanofi Pasteur Now Licensed by FDA
Sanofi Pasteur, the vaccines division of Sanofi announced today that the US Food and Drug Administration has approved the supplemental biologics license application (sBLA) for licensure of its four-strain influenza vaccine, Fluzone Quadrivalent vaccine.
Novartis Recalls Triaminic and Theraflu Syrups
Novartis Consumer Health, Inc. is voluntarily recalling certain lots of Triaminic® Syrups and Theraflu Warming Relief® Syrups that were manufactured in the United States prior to December 31, 2011.